Karyopharm’s shares cratered after Xpovio (selinexor) failed again to meet the progression-free survival primary endpoint in a Phase 3 endometrial cancer study. The readout, reported as XPORT-EC-042, marked the second Phase 3 miss for the blood-cancer drug’s expansion, intensifying scrutiny of the company’s broader development strategy. With cash of $91.2 million reported as of Q1, the company said it has limited runway into Q3 and is now evaluating financings and strategic alternatives. Despite the oncology setback, Karyopharm noted plans to submit an sNDA in August to request priority review and accelerated approval of Xpovio plus Jakafi for myelofibrosis, relying on overall survival data from the Sentry trial. The update reinforces how repeated late-stage failures can quickly shift biotech trajectory from pipeline execution to capital preservation and dealmaking.